ESR1 and breast cancer: Previous studies found that the risk of BC death among estrogen receptor (ER) and/or progesterone receptor (PR) positive patients, but not among those with triple-negative BC, was ≤4 times increased risk for NHB than for non-Hispanic White (NHW) patients [[4], [5], [6]].